Cargando…
Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study
BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-contro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219717/ https://www.ncbi.nlm.nih.gov/pubmed/28061869 http://dx.doi.org/10.1186/s12879-016-2150-6 |
_version_ | 1782492508951937024 |
---|---|
author | Noguchi, Taro Matsumura, Yasufumi Yamamoto, Masaki Nagao, Miki Takakura, Shunji Ichiyama, Satoshi |
author_facet | Noguchi, Taro Matsumura, Yasufumi Yamamoto, Masaki Nagao, Miki Takakura, Shunji Ichiyama, Satoshi |
author_sort | Noguchi, Taro |
collection | PubMed |
description | BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-control study in a Japanese university hospital between 2011 and 2012. We assessed the risk factors and clinical outcomes of bacteremia due to cefotaxime-non-susceptible Enterobacteriaceae (CTXNS-En) and analyzed the resistance mechanisms. RESULTS: Of 316 patients with Enterobacteriaceae bacteremia, 37 patients with bacteremia caused by CTXNS-En were matched to 74 patients who had bacteremia caused by cefotaxime-susceptible Enterobacteriaceae (CTXS-En). The most common CTXNS-En was Escherichia coli (43%), followed by Enterobacter spp. (24%) and Klebsiella spp. (22%). Independent risk factors for CTXNS-En bacteremia included previous infection or colonization of CTXNS-En, cardiac disease, the presence of intravascular catheter and prior surgery within 30 days. Patients with CTXNS-En bacteremia were less likely to receive appropriate empirical therapy and to achieve a complete response at 72 h than patients with CTXS-En bacteremia. Mortality was comparable between CTXNS-En and CTXS-En patients (5 vs. 3%). CTXNS-En isolates exhibited multidrug resistance but remained highly susceptible to amikacin and meropenem. CTX-M-type ESBLs accounted for 76% of the β-lactamase genes responsible for CTXNS E. coli and Klebsiella spp. isolates, followed by plasmid-mediated AmpC (12%). Chromosomal AmpC was responsible for 89% of CTXNS Enterobacter spp. isolates. CONCLUSIONS: CTXNS-En isolates harboring ESBL and AmpC caused delays in appropriate therapy among bacteremic patients. Risk factors and antibiograms may improve the selection of appropriate therapy for CTXNS-En bacteremia. Prevalent mechanisms of resistance in CTXNS-En were ESBL and chromosomal AmpC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-2150-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5219717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52197172017-01-10 Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study Noguchi, Taro Matsumura, Yasufumi Yamamoto, Masaki Nagao, Miki Takakura, Shunji Ichiyama, Satoshi BMC Infect Dis Research Article BACKGROUND: Cefotaxime plays an important role in the treatment of patients with bacteremia due to Enterobacteriaceae, although cefotaxime resistance is reported to be increasing in association with extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase (AmpC). METHODS: We conducted a case-control study in a Japanese university hospital between 2011 and 2012. We assessed the risk factors and clinical outcomes of bacteremia due to cefotaxime-non-susceptible Enterobacteriaceae (CTXNS-En) and analyzed the resistance mechanisms. RESULTS: Of 316 patients with Enterobacteriaceae bacteremia, 37 patients with bacteremia caused by CTXNS-En were matched to 74 patients who had bacteremia caused by cefotaxime-susceptible Enterobacteriaceae (CTXS-En). The most common CTXNS-En was Escherichia coli (43%), followed by Enterobacter spp. (24%) and Klebsiella spp. (22%). Independent risk factors for CTXNS-En bacteremia included previous infection or colonization of CTXNS-En, cardiac disease, the presence of intravascular catheter and prior surgery within 30 days. Patients with CTXNS-En bacteremia were less likely to receive appropriate empirical therapy and to achieve a complete response at 72 h than patients with CTXS-En bacteremia. Mortality was comparable between CTXNS-En and CTXS-En patients (5 vs. 3%). CTXNS-En isolates exhibited multidrug resistance but remained highly susceptible to amikacin and meropenem. CTX-M-type ESBLs accounted for 76% of the β-lactamase genes responsible for CTXNS E. coli and Klebsiella spp. isolates, followed by plasmid-mediated AmpC (12%). Chromosomal AmpC was responsible for 89% of CTXNS Enterobacter spp. isolates. CONCLUSIONS: CTXNS-En isolates harboring ESBL and AmpC caused delays in appropriate therapy among bacteremic patients. Risk factors and antibiograms may improve the selection of appropriate therapy for CTXNS-En bacteremia. Prevalent mechanisms of resistance in CTXNS-En were ESBL and chromosomal AmpC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-2150-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-07 /pmc/articles/PMC5219717/ /pubmed/28061869 http://dx.doi.org/10.1186/s12879-016-2150-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Noguchi, Taro Matsumura, Yasufumi Yamamoto, Masaki Nagao, Miki Takakura, Shunji Ichiyama, Satoshi Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title | Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title_full | Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title_fullStr | Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title_full_unstemmed | Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title_short | Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study |
title_sort | clinical and microbiologic characteristics of cefotaxime-non-susceptible enterobacteriaceae bacteremia: a case control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219717/ https://www.ncbi.nlm.nih.gov/pubmed/28061869 http://dx.doi.org/10.1186/s12879-016-2150-6 |
work_keys_str_mv | AT noguchitaro clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy AT matsumurayasufumi clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy AT yamamotomasaki clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy AT nagaomiki clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy AT takakurashunji clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy AT ichiyamasatoshi clinicalandmicrobiologiccharacteristicsofcefotaximenonsusceptibleenterobacteriaceaebacteremiaacasecontrolstudy |